Several other research analysts have also issued reports on the company. Morgan Stanley reiterated an underweight rating and issued a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Jefferies Group LLC restated a buy rating and issued a $70.00 target price (up previously from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Zacks Investment Research raised Bioverativ from a sell rating to a hold rating in a research report on Thursday, August 24th. Argus raised Bioverativ from a hold rating to a buy rating and set a $64.00 price target for the company in a research report on Wednesday, September 20th. Finally, Piper Jaffray Companies reissued an overweight rating and issued a $71.00 target price on shares of Bioverativ in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $60.93.
Bioverativ (NASDAQ:BIVV) opened at $50.76 on Monday. Bioverativ has a fifty-two week low of $40.00 and a fifty-two week high of $64.41.
ILLEGAL ACTIVITY WARNING: “Bioverativ Inc (BIVV) Given a $53.00 Price Target at Deutsche Bank AG” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/21/bioverativ-inc-bivv-given-a-53-00-price-target-at-deutsche-bank-ag.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new position in Bioverativ in the 3rd quarter valued at approximately $4,854,000. GSA Capital Partners LLP purchased a new stake in Bioverativ during the 3rd quarter valued at $2,097,000. Ameritas Investment Partners Inc. purchased a new stake in Bioverativ during the 3rd quarter valued at $2,530,000. Neuberger Berman Group LLC purchased a new stake in Bioverativ during the 3rd quarter valued at $563,000. Finally, California Public Employees Retirement System purchased a new stake in Bioverativ during the 3rd quarter valued at $12,886,000. 96.95% of the stock is currently owned by institutional investors and hedge funds.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.